Asia-Pacific In Vitro Diagnostics Market Overview:
Asia-Pacific IVD Market was valued at $12.9 billion in 2015, and is expected to reach $19.0 billion by 2022, supported by a CAGR of 5.6% during the forecast period 2015 - 2022. In vitro diagnostics (IVD) is a method used for detection and identification of diseases in an artificial environment using samples such as blood, urine, stool, tissues and other body fluids, which are derived from the human body. IVD includes several techniques such as immunodiagnostic, infectious diseases testing, blood testing, clinical chemistry, molecular diagnosis and other such techniques. Considerable increase in the number of chronic and infectious diseases, growing awareness towards healthcare solutions and technological advancements in healthcare industry encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.
The increased application of personalized medicines and widespread knowledge of rare diseases are boosting the growth of Asia Pacific IVD market. Moreover, growing need of IVD testing owing to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders drives the market growth. The Asia Pacific IVD market has evolved over the years with the launch of several innovative techniques used across multiple therapeutic areas. However, stringent regulatory policies and reimbursements issues in few countries limit the growth of this market. The rising demand for technologically advanced diagnostic devices, rise in GDP and per capita income and rise in disposable incomes facilitate a huge potential for the Asia Pacific IVD market in the Asia-Pacific region. Similarly, the development of a new range of condition-specific markers and tests along with the advancement in genomics and proteomics are creating new opportunities in emerging economies.
The Asia-Pacific IVD market is segmented based on product type, technique, indications, end user and country. Based on technique, the market is segmented into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry and other clinical technique. Immunodiagnostic is the highest revenue-generating segment in the overall IVD techniques market. However, the blood testing is the fastest growing technique in the overall IVD techniques market due to its ability to accurately detect the primary cause of the disease.
Based on product type, the market is segmented into instruments, reagents, services & software. Reagents held the highest market share in the Asia Pacific IVD market followed by rapidly growing instrument segment. Reagents are largely used in various equipment and play a key role in the overall diagnosis process. The application segment is categorized into infectious diseases, cancer, cardiac diseases, immune system diseases, nephrological diseases, gastrointestinal diseases, and others. Infectious diseases segment was the highest revenue-generating segment in 2015 and would continue to maintain its position throughout the forecast period, due to the rise in incidences of infectious diseases such as HIV/AIDS, Chlamydia and Hepatitis.
Hospitals and laboratories, academics & medical schools, point-of-care testing and others form the end users segment in the Asia-Pacific IVD market. Stand-alone laboratories generate the highest revenue, followed by hospitals. A significant rise in the number of hospitals and laboratories across the Asia-Pacific region along with increased awareness about developments in healthcare largely contribute to the growth of these segment.
Based on country, the Asia-Pacific IVD market is segmented into India, China, Japan, Australia, and other Asia-Pacific countries. Japan held the dominant share, around 35.3% in 2015 in the Asia-Pacific IVD market, owing to the high demand for testing in outpatient clinics, huge population base and rising medical insurance services by the Japan government. Moreover, China and Australia hold the significant market share due to the well-supported reimbursement facilities and well-regulated IVD devices, which comes under the regulation of medical devices. However, India registers highest CAGR i.e. 7.1% during the forecast period.
Product launch was the key strategy adopted by market payers, owing to the dynamic nature of the market in terms of technology advancement. The leading companies profiled in this report are, Danaher Corporation, Vela Diagnostics, Siemens AG, Affymetrix, Alere Inc., BioMerieux, Roche Diagnostics, Bio-Rad Laboratories, Becton, Dickinson And Company, Abbott Laboratories Inc., Arkray Inc., Sysmex Corporation, Johnson & Johnson, Siemens Healthcare and Trans Asia BioMedicals Ltd.
APAC IVD MARKET KEY BENEFITS:
- This report entails the detailed quantitative analysis of the current market and estimations from 2015 to 2022, which assists in identifying the prevailing market opportunities
- Exhaustive analysis of the Asia Pacific IVD market by product type helps in understanding the types of instruments and reagents that are currently being used during disease diagnostic that would gain prominence in the future
- Country-wise Asia Pacific IVD market conditions are comprehensively analyzed in this report. Increasing awareness about chronic diseases in developing economies is expected to drive the growth of the market
- Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
- Key market players within the Asia Pacific IVD market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of Asia Pacific IVD market
APAC IVD MARKET KEY SEGMENTS:
By Product type
- Software & Services
- Blood Testing
- Molecular Diagnostics
- Tissue Diagnostics
- Clinical Chemistry
- Other IVD Techniques
- Infectious Diseases
- Cardiac Diseases
- Immune System Disorders
- Nephrological Diseases
- Gastrointestinal Diseases
- Other Indications
By End Users
- Standalone Laboratory
- Academic & Medical Schools
- Point of Care